Allarity Therapeutics, Inc.
ALLRHealthcare|Biotechnology|US
$0.96
-0.01 (-1.13%)
DCF Value
$1.18
Tangible Book / Share
$0.22
Cash / Share
$1.07
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03878849 Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | Advanced Ovarian Cancer | P2 | Recruiting | 40 | RCT, Open-label | 2X-121, 2X-121 |
| NCT03877796 Clinical Pre-screening Protocol for Ovarian Cancer | Ovarian Cancer | Recruiting | 60 | — | — | |
| NCT03643107 Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | Metastatic Castration-Resistant Prostate Cancer Patients | P2 | Completed | 15 | Open-label | Irofulven |
| NCT03196947 Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP | Relapsed/Refractory Multiple Myeloma | P1P2 | Terminated | 1 | Open-label | APO010 |
| NCT04796324 Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | Metastatic Breast Cancer | P2 | Terminated | 13 | Open-label | Ixabepilone Injection |
| NCT01861496 Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours | Phase 1: Advanced or Refractory Solid Tumours, Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer | P1P2 | Completed | 50 | Open-label | LiPlaCis |
| NCT03562832 Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | Metastatic Breast Cancer | P2 | Completed | 20 | Open-label | PARP inhibitor 2X-121 |
| NCT05571969 Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 14 | Open-label | 2X-121 600 mg, 2X-121 800 mg, 2X-121 1000 mg |